Back to search results

Screening Program for Early Pancreatic Cancer Detection

This study is testing a new screening program to find pancreatic cancer early in people who have a higher chance of developing it. Pancreatic cancer can be hard to detect early, and this study aims to improve that. You might be able to join if you are between 50 and 85 years old, have recently developed a certain type of diabetes (glycemically-defined new-onset diabetes), and have an ENDPAC score of 3 or higher. The study will look at how well they can recruit participants, how many people complete imaging tests, and how successful blood sample collection is. This study does not have a specific phase listed and is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 100 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo blood sample collection, a CT scan with contrast (a special dye), and a review of your electronic health records.
Compensation
Not stated in the trial record.
Follow-up
The study will measure its primary goals for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07324096

A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer

Recruiting
NAAges 50–85InterventionalDiagnostic
Mayo Clinic
~100 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed Tomography with ContrastElectronic Health Record Review

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recruitment yield (Feasibility)
Measured over Up to 3 years
+3 more outcomes measured

Conditions

Pancreatic Ductal Adenocarcinoma

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT07324096

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ajit H. Goenka, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 50 and ≤ 85 years
Glycemically-defined new-onset diabetes (gNOD) with onset ≤ 180 days preceding enrollment
Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score ≥ 3, based on validated risk stratification models
Provide written or remote informed consent

Exclusion

Prior diagnosis of pancreatic ductal adenocarcinoma (PDA)
Known hereditary cancer syndromes (e.g., BRCA1/2, Lynch syndrome, Peutz-Jeghers)
Prior history of pancreatic surgery
Pancreatic cyst surveillance at time of registration
Contraindications to contrast-enhanced CT imaging per standard clinical practice at time of registration

What this trial measures

  • Recruitment yield (Feasibility)Up to 3 years

    Will assess the feasibility of protocol implementation as defined by recruitment yield (% of flagged high-risk individuals who consent). Descriptive statistics will be used to summarize feasibility endpoints.

  • Imaging adherence rates (Feasibility)Up to 3 years

    Will assess the feasibility of protocol implementation as defined by imaging adherence rates (% completing 3 scheduled computed tomography scans). Descriptive statistics will be used to summarize feasibility endpoints.

  • Blood collection success rates (Feasibility)Up to 3 years

    Will assess the feasibility of protocol implementation as defined by blood collection success rates (% completing 3 scheduled blood collections). Descriptive statistics will be used to summarize feasibility endpoints.

  • Completeness of electronic medical record (EMR)-based follow-up (Feasibility)Up to 3 years

    Will assess the feasibility of protocol implementation as defined by completeness of EMR-based follow-up (% of participants with outcome ascertainment). Descriptive statistics will be used to summarize feasibility endpoints.